Kalaris Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.4%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$2.03next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly104.9MTarget: Sufficient to fund operations into Q4 2027
Quarterly Net Loss Quarterly10.9MTarget: Minimize operational cash burn
Quarterly Research and Development (R&D) Expenses Quarterly7.6MTarget: Align with Phase 1b/2 clinical trial progression
Watch Items
- Phase 1b/2 Multiple Ascending Dose (MAD) Trial of TH103 in nAMDTrigger: Preliminary clinical data readoutAction: Evaluate safety, efficacy, and optimal dose selection to prepare for Phase 3 trials
- Phase 3 Clinical Trial InitiationTrigger: Year-end 2027Action: Initiate pivotal Phase 3 trials for TH103 in neovascular age-related macular degeneration (nAMD)
- Clinical Safety Profile (Intraocular Inflammation)Trigger: Any recurring patterns of intraocular inflammation in Phase 1b/2Action: Closely monitor safety data to ensure the dual-targeting VEGF/HSPG biologic maintains a favorable safety profile
Research as of 20 Jun 2026